Clinical trial
Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia
NCT00465751 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia
- Lead sponsor
- University Hospital, Basel, Switzerland
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- Not reported
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
familial combined hyperlipidemia, familial hypertriglyceridemia, metabolic syndrome